SCHEMBL2569765

SCHEMBL2569765

FC(F)(F)c1cccc2cccnc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMD14 O00487 2/20 0.55
COPS5 Q92905 2/20 0.55
KDM4E B2RXH2 3/20 0.54
CCR1 P32246 3/20 0.54
CCR5 P51681 3/20 0.54
CCR8 P51685 3/20 0.54
MMP2 P08253 2/20 0.54
TSHR P16473 2/20 0.54
LMNA P02545 2/20 0.54
MAPT P10636 2/20 0.54
ALOX15 P16050 2/20 0.54
HTT P42858 2/20 0.54
GMNN O75496 1/20 0.54
TP53 P04637 1/20 0.54
HSP90AA1 P07900 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
MMP9 P14780 1/20 0.54
NFKB1 P19838 1/20 0.54
MMP8 P22894 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29935933 1.00 PSMD14 (0.55) PSMD14COPS5KDM4ECCR1CCR5
Quinoline SCHEMBL28226310 0.89 ALDH1A1 (0.57) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL18434789 0.83 SLC40A1 (0.51) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL762337 0.83 KDM4E (0.54) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL22016210 0.81 CCR1 (0.52) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL11850412 0.81 LMNA (0.47) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL20505776 0.80 KDM4E (0.50) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL3901211 0.80 LMNA (0.45) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL13301166 0.80 PSMD14 (0.62) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL31619478 0.79 PARP1 (0.45) KDM4EMMP2TSHRLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119139301-A Application of 2, 8-trifluoromethyl quinoline derivative in preventing and treating cow mastitis pathogenic bacteria 兰州大学 2024-12-17 CN claimed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
CN-119139301-A Application of 2, 8-trifluoromethyl quinoline derivative in preventing and treating cow mastitis pathogenic bacteria 兰州大学 2024-12-17 CN disclosed
CN-119139301-A Application of 2, 8-trifluoromethyl quinoline derivative in preventing and treating cow mastitis pathogenic bacteria 兰州大学 2024-12-17 CN disclosed
CN-119139301-A Application of 2, 8-trifluoromethyl quinoline derivative in preventing and treating cow mastitis pathogenic bacteria 兰州大学 2024-12-17 CN disclosed
EP-3183250-B1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL CLAP CO LTD (KR) 2023-10-04 EP disclosed
EP-4198031-A1 TLR7/8 ANTAGONISTS AND USES THEREOF Merck Patent GmbH (DE) 2023-06-21 EP disclosed
EP-3497094-B1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-02-15 EP disclosed
EP-3183757-B1 ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM CLAP CO LTD (KR) 2022-05-04 EP disclosed
WO-2022083731-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME 健艾仕生物医药有限公司 2022-04-28 WO disclosed
EP-0696291-A1 PYRIDO(1,2,3-DE)QUINOXALINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND THEIR USE IN MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 1996-02-14 EP disclosed
EP-0363212-B1 Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components MITSUI TOATSU CHEMICALS (JP) 1995-01-04 EP disclosed
WO-1994025472-A1 PYRIDO(1,2,3-DE)QUINOXALINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND THEIR USE IN MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 1994-11-10 WO disclosed
US-5204348-A Quinoline derivatives MITSUI TOATSU CHEMICALS INC. (JP) 1993-04-20 US disclosed
US-5112817-A Anticancer Drug Potentiators MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1992-05-12 US disclosed
EP-0363212-A2 Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-04-11 EP disclosed
US-4396620-A BACTERICIDES ELI LILLY AND COMPANY (US) 1983-08-02 US disclosed
US-4382931-A 3'-Substituted quinolinium cephalosporins ELI LILLY AND COMPANY (US) 1983-05-10 US disclosed
US-4053318-A SENSITIZING MEROCYANINE DYE FUJI PHOTO FILM CO., LTD. (JA) 1977-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR PSMD14 3560/4885COPS5 672/4885KDM4E 3646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.